IHC evaluating forkhead box P3 (FOXP3) (an anti-tumoral T cell marker) and T-cell immunoglobulin and mucin domain 3 (TIM-3) in conjunction with TLS presence found that elevation of these markers are associated with longer RFS in patients with NMIBC receiving BCG [38]. Here, FOXP3 is linked to Tumor Lysis Syndrome.